An adverse tumor-protective effect of IDO1 inhibition

[1]  D. Lambrechts,et al.  A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma , 2022, bioRxiv.

[2]  Ronen Levy,et al.  Anti-tumour immunity induces aberrant peptide presentation in melanoma , 2020, Nature.

[3]  L. Brochez,et al.  IDO Expression in Cancer: Different Compartment, Different Functionality? , 2020, Frontiers in Immunology.

[4]  K. Flaherty,et al.  Reversal of pre-existing NGFR-driven tumor and immune therapy resistance , 2020, Nature Communications.

[5]  D. Peeper,et al.  Rational Cancer Treatment Combinations: An Urgent Clinical Need. , 2020, Molecular cell.

[6]  T. Schumacher,et al.  Long-distance modulation of bystander tumor cells by CD8+ T cell-secreted IFNγ , 2020, Nature Cancer.

[7]  E. Holland,et al.  Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy , 2020, Oncoimmunology.

[8]  James R. Anderson,et al.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. , 2019, The Lancet. Oncology.

[9]  T. Schumacher,et al.  Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold , 2019, Cell.

[10]  C. Goding,et al.  MITF—the first 25 years , 2019, Genes & development.

[11]  J. Madore,et al.  Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. , 2019, Cancer cell.

[12]  D. Adams,et al.  XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data , 2018, BMC Bioinformatics.

[13]  G. Prendergast,et al.  Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond , 2018, Seminars in Immunopathology.

[14]  Companies Scaling Back IDO1 Inhibitor Trials. , 2018, Cancer discovery.

[15]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[16]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[17]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[18]  Matthew J. Daniels,et al.  Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma , 2017, Genes & development.

[19]  Mila Ljujic,et al.  The integrated stress response , 2016, EMBO reports.

[20]  D. Adams,et al.  BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts , 2016, Cell reports.

[21]  Reuven Agami,et al.  Tumour-specific proline vulnerability uncovered by differential ribosome codon reading , 2016, Nature.

[22]  T. Graeber,et al.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.

[23]  K. Flaherty,et al.  The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. , 2014, Cancer discovery.

[24]  Ton N Schumacher,et al.  Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. , 2014, Human gene therapy methods.

[25]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[26]  J. Mesirov,et al.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.

[27]  Y. Cheng,et al.  Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors , 2014, Clinical Cancer Research.

[28]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[29]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[30]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[31]  L. Chin,et al.  Melanoma: from mutations to medicine. , 2012, Genes & development.

[32]  Rui-Ru Ji,et al.  An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.

[33]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[34]  K. Hoek,et al.  Cancer stem cells versus phenotype‐switching in melanoma , 2010, Pigment cell & melanoma research.

[35]  Jiangbin Ye,et al.  The GCN2‐ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation , 2010, The EMBO journal.

[36]  J. Masters,et al.  Detection of Mycoplasma in cell cultures , 2010, Nature Protocols.

[37]  C. Bertolotto,et al.  Fifteen‐year quest for microphthalmia‐associated transcription factor target genes , 2010, Pigment cell & melanoma research.

[38]  Gary Box,et al.  CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. , 2008, Cancer research.

[39]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[40]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[42]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[43]  R. Delston,et al.  MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A , 2005, The Journal of cell biology.

[44]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[45]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[46]  H. Pehamberger,et al.  The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. , 2002, Cancer research.

[47]  M. Schapira,et al.  Regulated translation initiation controls stress-induced gene expression in mammalian cells. , 2000, Molecular cell.

[48]  A. Hinnebusch,et al.  Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. , 2000, Molecular cell.

[49]  D. Munn,et al.  Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.

[50]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[51]  Richard Graham Knowles,et al.  THE role of indoleamine 2,3‐dioxygenase in the anti‐tumour activity of human interferon‐γ in vivo , 1995 .

[52]  O. Takikawa,et al.  Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. , 1988, The Journal of biological chemistry.

[53]  M. Edelstein,et al.  Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[54]  O. Hayaishi,et al.  Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. , 1981, Proceedings of the National Academy of Sciences of the United States of America.